A Phase II study of M528101 for postherpetic neuralgia

A Phase II, placebo-controlled, randomized, double-blind, parallel-group, single-center study to evaluate efficacy and safety of M528101 in patients with postherpetic neuralgia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031220415

Enrollment

Registered

2022-10-27

Start date

2022-11-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postherpetic neuralgia

Interventions

Apply an appropriate amount of M5281 to the affected area

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Postherpetic neuralgia patients aged 18 years and older

Exclusion criteria

Exclusion criteria: (1)Patients with herpes zoster skin symptoms (edematous erythema, blisters, erosions, crusts) or other epidermal abrasions (erosions, ulcers, fissures) at the drug administration site (postherpetic neuralgia expression site) (2)Patients with symptoms or treatment history (including neurodestructive drugs and radiofrequency thermocoagulation) that the investigator (subinvestigator) judges may affect the pain NRS evaluation of postherpetic neuralgia (3)Patients who have or are currently undergoing drug treatment with opioids for postherpetic neuralgia

Design outcomes

Primary

Measure	Time frame
Numerical Rating Scale (NRS)	—

Contacts

Public Contact- Clinical Trials Information

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-75-325-3279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026